Borylative cyclisation of diynes using BCl3 and borocations.

The borylative cyclisation of 1,2-dialkynyl benzenes with BCl3 leads to dibenzopentalenes (via intramolecular SEAr) or benzofulvenes (via chloride addition) depending on substituents, with stabilised vinyl cation intermediates (e.g. with a p-MeO-C6H4-group) favouring the latter. The use of borocations leads to more selective dibenzopentalene formation, while other diyne frameworks undergo intramolecular SEAr selectively even with p-MeO groups.

BCl3 -Induced Annulative Oxo- and Thioboration for the Formation of C3-Borylated Benzofurans and Benzothiophenes.

BCl3 -induced borylative cyclization of aryl-alkynes possessing ortho-EMe (E=S, O) groups represents a simple, metal-free method for the formation of C3-borylated benzothiophenes and benzofurans. The dichloro(heteroaryl)borane primary products can be protected to form synthetically ubiquitous pinacol boronate esters or used in situ in Suzuki-Miyaura cross couplings to generate 2,3-disubstituted heteroarenes from simple alkyne precursors in one pot. In a number of cases alkyne trans-haloboration occurs alongside, or instead of, borylative cyclization and the factors controlling the reaction outcome are determined.

Formation of C(sp(2))-boronate esters by borylative cyclization of alkynes using BCl3.

BCl3 is an inexpensive electrophile which induces the borylative cyclization of a wide range of substituted alkynes to regioselectively form polycycles containing synthetically versatile C(sp(2) )boronate esters. It proceeds rapidly, with good yields and is compatible with a range of functional groups and substitution patterns. Intermolecular 1,2-carboboration of alkynes is also achieved using BCl3 to generate trisubstituted vinyl boronate esters.

C(sp3)-H activation without a directing group: regioselective synthesis of N-ylide or N-heterocyclic carbene complexes controlled by the choice of metal and ligand.

N-Ylide complexes of Ir have been generated by C(sp(3))-H activation of α-pyridinium or α-imidazolium esters in reactions with [Cp*IrCl2]2 and NaOAc. These reactions are rare examples of C(sp(3))-H activation without a covalent directing group, which-even more unusually-occur α to a carbonyl group. For the reaction of the α-imidazolium ester [3H]Cl, the site selectivity of C-H activation could be controlled by the choice of metal and ligand: with [Cp*IrCl2]2 and NaOAc, C(sp(3))-H activation gave the N-ylide complex 4; in contrast, with Ag2O followed by [Cp*IrCl2]2, C(sp(2))-H activation gave the N-heterocyclic carbene complex 5. DFT calculations revealed that the N-ylide complex 4 was the kinetic product of an ambiphilic C-H activation. Examination of the computed transition state for the reaction to give 4 indicated that unlike in related reactions, the acetate ligand appears to play the dominant role in C-H bond cleavage.

An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

INTRODUCTION/BACKGROUND: An individual patient data metaanalysis was performed to determine clinical outcomes, and to propose a risk stratification system, related to the comprehensive treatment of patients with oligometastatic NSCLC. MATERIALS AND METHODS: After a systematic review of the literature, data were obtained on 757 NSCLC patients with 1 to 5 synchronous or metachronous metastases treated with surgical metastectomy, stereotactic radiotherapy/radiosurgery, or radical external-beam radiotherapy, and curative treatment of the primary lung cancer, from hospitals worldwide. Factors predictive of overall survival (OS) and progression-free survival were evaluated using Cox regression. Risk groups were defined using recursive partitioning analysis (RPA). Analyses were conducted on training and validating sets (two-thirds and one-third of patients, respectively). RESULTS: Median OS was 26 months, 1-year OS 70.2%, and 5-year OS 29.4%. Surgery was the most commonly used treatment for the primary tumor (635 patients [83.9%]) and metastases (339 patients [62.3%]). Factors predictive of OS were: synchronous versus metachronous metastases (P < .001), N-stage (P = .002), and adenocarcinoma histology (P = .036); the model remained predictive in the validation set (c-statistic = 0.682). In RPA, 3 risk groups were identified: low-risk, metachronous metastases (5-year OS, 47.8%); intermediate risk, synchronous metastases and N0 disease (5-year OS, 36.2%); and high risk, synchronous metastases and N1/N2 disease (5-year OS, 13.8%). CONCLUSION: Significant OS differences were observed in oligometastatic patients stratified according to type of metastatic presentation, and N status. Long-term survival is common in selected patients with metachronous oligometastases. We propose this risk classification scheme be used in guiding selection of patients for clinical trials of ablative treatment.